GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » EV-to-EBITDA

Calidi Biotherapeutics (Calidi Biotherapeutics) EV-to-EBITDA : -1.84 (As of May. 17, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Calidi Biotherapeutics's enterprise value is $17.18 Mil. Calidi Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-9.34 Mil. Therefore, Calidi Biotherapeutics's EV-to-EBITDA for today is -1.84.

The historical rank and industry rank for Calidi Biotherapeutics's EV-to-EBITDA or its related term are showing as below:

CLDI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.18   Med: -5.45   Max: -1.14
Current: -1.84

During the past 4 years, the highest EV-to-EBITDA of Calidi Biotherapeutics was -1.14. The lowest was -17.18. And the median was -5.45.

CLDI's EV-to-EBITDA is ranked worse than
100% of 457 companies
in the Biotechnology industry
Industry Median: 9.79 vs CLDI: -1.84

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Calidi Biotherapeutics's stock price is $0.242. Calidi Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.372. Therefore, Calidi Biotherapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Calidi Biotherapeutics EV-to-EBITDA Historical Data

The historical data trend for Calidi Biotherapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics EV-to-EBITDA Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - - -2.19

Calidi Biotherapeutics Quarterly Data
Dec20 Sep21 Dec21 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - - - -12.67 -2.19

Competitive Comparison of Calidi Biotherapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Calidi Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calidi Biotherapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's EV-to-EBITDA falls into.



Calidi Biotherapeutics EV-to-EBITDA Calculation

Calidi Biotherapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=17.183/-9.335
=-1.84

Calidi Biotherapeutics's current Enterprise Value is $17.18 Mil.
Calidi Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calidi Biotherapeutics  (AMEX:CLDI) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Calidi Biotherapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.242/-0.372
=At Loss

Calidi Biotherapeutics's share price for today is $0.242.
Calidi Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.372.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Calidi Biotherapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines